Antidote-mediated control of an anticoagulant aptamer in vivo

被引:272
|
作者
Rusconi, CP
Roberts, JD
Pitoc, GA
Nimjee, SM
White, RR
Quick, G
Scardino, E
Fay, WP
Sullenger, BA
机构
[1] Duke Univ, Med Ctr, Dept Surg, Ctr Translat Res, Durham, NC 27710 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nbt1023
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote control is the safest way to regulate drug activity, because unlike rapidly clearing drugs, control of the drug activity is independent of underlying patient physiology and co-morbidities. Until recently, however, there was no general method to discover antidote-controlled drugs. Here we demonstrate that the activity and side effects of a specific class of drugs, called aptamers, can be controlled by matched antidotes in vivo. The drug, an anticoagulant aptamer, systemically induces anticoagulation in pigs and inhibits thrombosis in murine models. The antidote rapidly reverses anticoagulation engendered by the drug, and prevents drug-induced bleeding in surgically challenged animals. These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals.
引用
收藏
页码:1423 / 1428
页数:6
相关论文
共 50 条
  • [1] Antidote-mediated control of an anticoagulant aptamer in vivo
    Christopher P Rusconi
    Joseph D Roberts
    George A Pitoc
    Shahid M Nimjee
    Rebekah R White
    George Quick
    Elizabeth Scardino
    William P Fay
    Bruce A Sullenger
    Nature Biotechnology, 2004, 22 : 1423 - 1428
  • [2] Selection of an Aptamer Antidote to the Anticoagulant Drug Bivalirudin
    Martin, Jennifer A.
    Parekh, Parag
    Kim, Youngmi
    Morey, Timothy E.
    Sefah, Kwame
    Gravenstein, Nikolaus
    Dennis, Donn M.
    Tan, Weihong
    PLOS ONE, 2013, 8 (03):
  • [3] Antidote reversal of a novel prothrombin aptamer anticoagulant
    Bompiani, K. M.
    Oney, S.
    Church, F. C.
    Sullenger, B. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 690 - 690
  • [4] ANTICOAGULANT ANTIDOTE
    Arnaud, Celia
    CHEMICAL & ENGINEERING NEWS, 2014, 92 (44) : 6 - 6
  • [5] Regulation of Thrombin Activity with a Bifunctional Aptamer and Hemin: Development of a New Anticoagulant and Antidote Pair
    Wang, Jing
    Cao, Ya
    Chen, Guifang
    Li, Genxi
    CHEMBIOCHEM, 2009, 10 (13) : 2171 - 2176
  • [6] Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant
    Soule, Erin E.
    Bompiani, Kristin M.
    Woodruff, Rebecca S.
    Sullenger, Bruce A.
    NUCLEIC ACID THERAPEUTICS, 2016, 26 (01) : 1 - 9
  • [7] In Vivo applications of an antidote-controlled anticoagulant targeting coagulation factor IXa
    Rusconi, CP
    Roberts, JD
    Pitoc, GA
    Nimjee, SM
    White, RR
    Fay, WP
    Sullenger, BA
    CIRCULATION, 2003, 108 (17) : 138 - 138
  • [8] Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
    Bompiani, K. M.
    Woodruff, R. S.
    Becker, R. C.
    Nimjee, S. M.
    Sullenger, B. A.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (10) : 1924 - 1934
  • [9] FDA approves anticoagulant antidote
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (12) : 811 - 811
  • [10] FDA approves anticoagulant antidote
    Asher Mullard
    Nature Reviews Drug Discovery, 2015, 14 : 811 - 811